Skip to main content
Premium Trial:

Request an Annual Quote

Trading Plans

Oxford Nanopore has released plans to be traded on the London stock exchange, Reuters reports.

The company announced earlier this year that it was preparing for an initial public offering in the second half of 2021.

Reuters adds that Oxford Nanopore is planning a free float of at least 25 percent of its shares in its IPO. According to the Financial Times, analysts say the company could be valued at £4 billion (US $5.5 billion), based on its 2023 revenue target and comparisons with competitors. The Evening Standard adds that a recent funding round suggests the company may currently have a £2.5 billion valuation.

Oxford Nanopore spun out of Oxford University in 2005, and FT says its sequencing machines are currently being used to identify and track the spread of SARS-CoV-2 variants in 85 countries. The company, which mostly has users at universities and other scientific research labs, additionally plans to move into applied genomics fields like pharmaceuticals, agriculture, and water safety, it notes.

Reuters adds that this would also be a feat for the London exchange, as most British pharmaceutical and life science companies are listed on New York's Nasdaq exchange.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more